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A retrospective observational study in Taiwan, 1998–
2004, identiﬁ  ed 92 patients with group G streptococcal bac-
teremia; 86 had Streptococcus dysgalactiae subspecies 
equisimilis. The most common diagnosis was cellulitis (48 
cases), followed by primary bacteremia (34 cases). Infec-
tion recurred in 9 patients. Mortality rate was low (3.3%); 
resistance to quinupristin-dalfopristin was high.
G
roup G streptococci (GGS) are part of the normal mi-
crobial ﬂ  ora of the gastrointestinal tract, vagina, and 
skin and cause a variety of infections (1). Major underlying 
illnesses in patients with GGS bacteremia are malignancy, 
cardiovascular disease, diabetes mellitus, bone and joint 
diseases, and cirrhosis (1,2). Reported mortality rates for 
patients with GGS bacteremia also vary, ranging from 5% 
to 30% (1–3). Recent studies of β-hemolytic streptococci 
isolates carrying Lanceﬁ  eld group G antigen showed that 
they consist of Streptococcus dysgalactiae subspecies eq-
uisimilis, S. anginosus, and S. canis (2,4–6). To supplement 
the limited clinical information about bacteremia caused by 
GGS strains identiﬁ  ed to the species level (2–4), we con-
ducted a retrospective observational study.
The Study
We included all patients with GGS-positive blood cul-
tures who had been treated from April 1998 through August 
2004 at National Taiwan University Hospital, a 2,000-bed 
teaching hospital in northern Taiwan. We recorded demo-
graphic parameters, underlying illness, clinical diagnosis, 
and outcome for each patient. Clinical diagnosis was based 
on the attending physician’s judgment and examination 
results. Recurrence of bacteremia was deﬁ  ned as repeated 
positive blood culture after complete treatment (at least 14 
days) of previous bacteremia.
Differentiation of GGS was based on colony size, 
hemolytic reaction, Voges-Proskauer reaction, and 
β-glucuronidase activity. All β-hemolytic streptococci, 
whether large or small colonies, were tested for Lanceﬁ  eld 
group by using an agglutination kit (Streptex; Murex Bio-
tech Ltd., Dartford, UK). PCR to differentiate between S. 
anginosus and S. dysgalactiae subsp. equisimilis was per-
formed for all GGS isolates as described (7). For identi-
ﬁ  cation of S. canis, a probable isolate was identiﬁ  ed by a 
negative β-glucuronidase result and further conﬁ  rmed with 
the 16sRNA method as described (8). Susceptibilities of 
these isolates were tested by using the broth microdilution 
method as deﬁ  ned by the Clinical and Laboratory Stan-
dards Institute (formerly National Committee for Clinical 
Laboratory Standards) (9).
To determine the similarity of isolates in cases of re-
currence, we used pulsed-ﬁ  eld gel electrophoresis (PFGE) 
as described (10). The emm typing of isolates in cases of re-
currence were also determined as described (11). The ﬁ  rst 
160 bases sequenced by emmseq2 that had >95% identity 
were deﬁ  ned as having the same genotype (11).
During the study period, 106 episodes of GGS bac-
teremia in 92 patients had been recorded; 56 episodes oc-
curred during the ﬁ  rst half of the study period (before June 
2001) and 50 episodes during the second half. The caus-
ative agent was S. dysgalactiae subsp. equisimilis for 99 
episodes, S. anginosus for 5, and S. canis for 2. Bacteremia 
recurred for 9 patients (1 had 4 episodes, and 3 had 3 epi-
sodes); bacteremia was nosocomial for 7 patients and poly-
microbial for 5. The clinical characteristics of the patients 
are summarized in Table 1. All 3 patients who died had a 
diagnosis of the primary bacteremia caused by S. dysgalac-
tiae subsp. equisimilis.
Among the 9 patients with recurrent bacteremia, the 
causative agent was S. dysgalactiae subsp. equisimilis for 
8 and S. canis for 1. PFGE performed with all 13 available 
isolates from recurrent cases showed that 10 were identical 
to that of the initial episode, including 1 in a patient with 
recurrence of S. canis bacteremia. Sequence typing showed 
emm type stG485 for 4 patients. The clinical characteristics 
of the patients and emm typing results are shown in Table 
2; PFGE results are shown in the Figure. The underlying 
diseases of patients with recurrent episodes included geni-
tal cancer (4 [44.4%] patients) and history of cellulitis (6 
[66.7%]), each of which was signiﬁ  cantly correlated with 
the likelihood of recurrence (p<0.01 for each). Further 
analysis showed that a previous history of cellulitis was 
signiﬁ  cantly correlated with female sex (p = 0.01), genital 
cancer (p<0.01), tissue edema (p = 0.02), heart disease (p = 
0.04), and post–coronary artery bypass graft (p = 0.03).
Bacteremia caused by β-hemolytic S. anginosus with 
group G antigen was identiﬁ  ed for 5 patients, none of whom 
had cellulitis, compared with 48 (55.8%) of the 86 patients 
with S. dysgalactiae subsp. equisimilis who did have cel-
lulitis (p = 0.03). Polymicrobial bacteremia and nosocomial 
bacteremia were found in a higher percentage of patients 
with S. anginosus (60% and 40.0%, respectively) than of 
patients with S. dysgalactiae subsp. equisimilis bacteremia 
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wan University College of Medicine, Taipei, Taiwan(4.7% and 5.8%, respectively); p<0.01 and p = 0.02, re-
spectively. The 1 patient with S. canis bacteremia was a 33-
year-old man with no history of dog bite. He had alcohol-
associated liver cirrhosis of Child C (severe) classiﬁ  cation 
and leg edema. He had 2 episodes of S. canis bacteremia 1 
month apart. Echocardiogram results showed no evidence 
of valvular vegetation. For the ﬁ  rst episode, the patient re-
ceived a 14-day course of cefotaxime. 
Antimicrobial drug–susceptibility testing showed 
decreased susceptibility to only macrolides (susceptibity 
rates: azithromycin 67.4%, clarithromycin 73.9%), clin-
damycin (87.0%), and quinupristin-dalfopristin (33.7%) 
(online Appendix Table, available from www.cdc.gov/
EID/content/14/5/837-appT.htm).  No clinical factor cor-
related with macrolide resistance. All isolates of recurrent 
bacteremia were susceptible to macrolides.
Conclusions
We documented 5 cases of primary bacteremia caused 
by β-hemolytic group G S. anginosus and unintentionally 
documented recurrence of S. canis bacteremia. S. canis bac-
teremia in humans was ﬁ  rst clearly described in 1997 (12). 
Our  ﬁ   nding of 5 β-hemolytic  S. anginosus isolates 
and 1 S. canis isolate in patients with GGS bacteremia in 
this study differs from ﬁ  ndings of previous studies (2,3). 
Factors that may have contributed to this discrepancy in-
clude serotype determination and PCR method. Serotype 
determination was performed for all β-hemolytic strepto-
cocci isolated in our hospital, whether colonies were large 
or small, which might have led to the detection of more 
streptococcal isolates with G antigen. The PCR method 
developed in our hospital and used in this study could ef-
fectively differentiate S. anginosus from S. dysgalactiae 
subsp. equisimilis (7). 
Information about clinical infection with S. milleri 
with group G antigen is limited (4). In a previous study 
of GGS bacteremia, Cohen-Poradosu et al. reported that 6 
of 84 patients had recurrence of bacteremia (3). We found 
recurrence in 9 of the 92 patients. Risk factors were similar 
to those previously reported for non–group A streptococcal 
cellulitis (13). PFGE of these isolates showed that a high 
percentage of recurrence was caused by identical strains. 
Although Cohen-Poradosu et al. reported that emm type 
stG840 was the most common strain (3), we found emm 
type stG485 to be most common.
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Table 1. Clinical characteristic of 92 patients with group G 
streptococcal bacteremia, April 1998–August 2004, Taiwan
Characteristic No. (%) patients 
Age, y 
 <10  1  (1.1) 
 10–50  12  (13.0) 
 51–75  68  (73.9) 
 >75  11  (12.0) 
  Median (range)  72 (10–93) 
Sex 
 Male  58  (63.0) 
   Female  34 (37.0) 
Underlying diseases 
 Malignancy  35  (38.0) 
 Genital  10  (10.9) 
  Head and neck  8 (8.7) 
 Gastrointestinal  6  (6.5) 
 Hematologic  3  (3.3) 
  Tissue edema  25 (27.2) 
  Heart disease  20 (21.7) 
  Post–coronary artery bypass graft  6 (6.5) 
  Diabetes mellitus  16 (17.4) 
  Central nervous system disease  15 (16.3) 
  Liver cirrhosis  9 (9.8) 
  Chronic renal disease  8 (8.7) 
  Chronic lung disease  6 (6.5) 
  Bone disease  5 (5.4) 
  Deep venous thrombosis  2 (2.2) 
Type of infection 
 Cellulitis  48  (52.1)* 
  Primary bacteremia  34 (36.9) 
 Deep-seated  abscess  4 (4.2)†
  Neutropenia and fever  3 (3.3) 
  Septic arthritis  2 (2.2) 
  Urinary tract infection  1 (1.1) 
  Infective endocarditis  1 (1.1) 
 Pneumonia  1  (1.1) 
Initial findings 
 Fever  86  (93.5) 
  Leukocytosis (>10,000 cells/PL) 34 (37.0) 
  Septic shock  4 (5.4) 
Outcome
 Death  3  (3.3) 
  Recurrence of bacteremia  9 (9.8) 
*Includes 2 patients who also had septic arthritis. 
†Includes 2 patients with psoas muscle abscess, 1 with epidural abscess, 
and 1 with deep neck infection. 
Figure. Pulsed-ﬁ  eld gel electrophoresis proﬁ  les of all isolates from 
patients with recurrent group G streptococcal bacteremia. Isolates 
B1 and B2, Streptococcus canis; other isolates, S. dysgalactiae 
subsp. equisimilis (see designation of the isolates in Table 2). Lane 
M, molecular mass markerBacteremia Caused by Group G Streptococci, Taiwan
For years in Taiwan, macrolide resistance of strepto-
cocci has been a major health problem (14,15). A previ-
ous study found erythromycin resistance in 23.5% of GGS 
strains (14). Although we did not test for erythromycin 
resistance, we found some resistance even to new mac-
rolides. Since restriction of macrolide use in Taiwan, a 
linear relationship has been noted between the decline in 
erythromycin use and the decline in erythromycin resis-
tance in S. pyogenes (15). Our study, however, found no 
decline in macrolide resistance from ﬁ  rst half of the study 
period (27.1%) to the second half (37.0%).
In summary, in our study, infection with S. dysga-
lactiae subsp. equisimilis was the most common cause of 
GGS bacteremia. Infection recurred for ≈10%. The mortal-
ity rate for patients with GGS bacteremia was relatively 
low (<10%), but resistance to quinupristin-dalfopristin was 
extremely high.
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sex Isolate Date of isolation  Underlying disease  Clinical diagnosis  emm type 
PFGE 
pattern
1 67/F A1 2001 May 28   Cellulitis stG166b –
A2 2002 Jul 18  Cellulitis stG166b Identical
A3 2003 Oct 14 
Coronary heart disease, post–
coronary artery bypass graft 
Cellulitis stG166b Identical
2 33/M B1† 2002 Nov 13  Primary bacteremia  STL1929.1 – 
B2† 2002 Oct 15 
Alcoholic liver cirrhosis, child C 
Primary bacteremia  STL1929.1 Identical 
3 47/F C1 1998 May 15  Cellulitis stG166b –
C2 2002 Jan 18  Cellulitis stG6.1 Related
C3 2002 Dec 19 
Vulvar cancer after surgery and 
radiotherapy 
Cellulitis stG6.1  Identical
4 49/M D1 2000 May 24  Cellulitis stG485 –
D2 2000 Aug 9 
Nasopharyngeal carcinoma after 
chemotherapy and radiotherapy  Cellulitis stG485 Identical
5 28/M E1 1998 Dec 26  Cellulitis stG485 –
E2 1999 Aug 28 
von Willebrand disease, type I 
Cellulitis stG840 Different
6 72/F F1 1998 Aug 24  Cellulitis stG485 –
F2 1998 Oct 23  Cellulitis stG485 Identical
F3 1999 Dec 3 
Cervical cancer after surgery and 
radiotherapy, diabetes mellitus 
Cellulitis stG840 Different
7 55/F G1 1999 Oct 9  Cellulitis stG485 –
G2 2000 Apr 18  Cellulitis stG485 Identical
G3 2001 Sep 24  Cellulitis stG485 Identical
NA 2000 Jul 19 
Cervical cancer after surgery and 
radiotherapy 
Cellulitis NA NA
8 46/M H1 2001 Aug 21  Primary bacteremia  stGLP 1.0  –
H2 2001 Sep 6 
Acute myeloid leukemia (M4) 
Primary bacteremia  stGLP 1.0  Identical
9 80/F I1 2003 May 5  Primary bacteremia  stG245.0 –
I2 2003 Nov 17 
Cervical cancer with lung metastasis 
and obstructive uropathy  Primary bacteremia  stG245.0 Identical
*PFGE, pulsed-field gel electrophoresis; NA, not available. 
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